Antiretroviral therapy coverage among people living with hiv in Kazakhstan
Kazakhstan: Antiretroviral therapy coverage among people living with hiv was 74 in 2024. ◆ Volatile
Antiretroviral therapy coverage among people living with hiv in Kazakhstan, 2000–2024
Source: Our World in Data.
Analysis
Kazakhstan recorded 74 for antiretroviral therapy coverage among people living with hiv in 2024. That is the highest value across all 25 years on record.
The figure is up 5.7% on the previous year and up 270.0% over ten years.
Over the whole period, antiretroviral therapy coverage among people living with hiv in Kazakhstan peaked at 74 in 2024 and was at its lowest, 0, in 2000.
That places Kazakhstan 66th out of 143 countries with data for 2024, putting it in the middle of the range.
The series is highly variable year to year, so single readings are best treated with caution.
Antiretroviral therapy coverage among people living with hiv in Kazakhstan, year by year
| Year | Value | Change |
|---|---|---|
| 2000 | 0 | — |
| 2001 | 0 | — |
| 2002 | 0 | — |
| 2003 | 0 | — |
| 2004 | 0 | — |
| 2005 | 3 | — |
| 2006 | 3 | +0.0% |
| 2007 | 4 | +33.3% |
| 2008 | 5 | +25.0% |
| 2009 | 7 | +40.0% |
| 2010 | 8 | +14.3% |
| 2011 | 10 | +25.0% |
| 2012 | 13 | +30.0% |
| 2013 | 17 | +30.8% |
| 2014 | 20 | +17.6% |
| 2015 | 24 | +20.0% |
| 2016 | 28 | +16.7% |
| 2017 | 38 | +35.7% |
| 2018 | 47 | +23.7% |
| 2019 | 52 | +10.6% |
| 2020 | 56 | +7.7% |
| 2021 | 60 | +7.1% |
| 2022 | 65 | +8.3% |
| 2023 | 70 | +7.7% |
| 2024 | 74 | +5.7% |
Kazakhstan compared with similar countries
- Kazakhstan's 74 is above the median for upper middle income countries, which is 65.5, 1.1× the median. (40 countries reporting)
- Kazakhstan's 74 is below the median for Europe & Central Asia, which is 83, 89% of the median. (34 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 2.2 | 0 | 7 | 10 |
| 2010s | 25.7 | 8 | 52 | 10 |
| 2020s | 65 | 56 | 74 | 5 |
Countries ranked near Kazakhstan
More health data for Kazakhstan
- Un projection of annual infant deaths, annual growth rate -1.35 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.3158 % change on previous year (2090)
- Un projection of annual infant deaths 660 (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -1.58 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0485 units per person (2025)
- Population ages 00-04, male, annual growth rate -1.16 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, male, per capita 0.0515 units per person (2025)
Frequently asked questions
- What is antiretroviral therapy coverage among people living with hiv in Kazakhstan?
- Antiretroviral therapy coverage among people living with hiv in Kazakhstan was 74 in 2024, according to Our World in Data.
- What is the highest antiretroviral therapy coverage among people living with hiv recorded in Kazakhstan?
- The highest recorded value was 74 in 2024.
- What is the lowest antiretroviral therapy coverage among people living with hiv recorded in Kazakhstan?
- The lowest recorded value was 0 in 2000.
- How does Kazakhstan rank for antiretroviral therapy coverage among people living with hiv?
- Kazakhstan ranks 66th out of 143 countries with data for 2024.
- Is antiretroviral therapy coverage among people living with hiv rising or falling in Kazakhstan?
- Over the last ten years it is up 270.0%. The long-run trend across the full record is volatile.
- Where does this Kazakhstan data come from?
- The figures come from Our World in Data, published as part of Antiretroviral therapy coverage among people living with hiv. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (Our World in Data).